Key result
Hematopoietic colony-stimulating factors given with vincristine are linked to severe atypical neuropathy.
Why the study?
Does the administration of hematopoietic colony-stimulating factors (CSFs) increase the risk of severe atypical neuropathy in lymphoma patients treated with vincristine?
Population
54 adult and pediatric patients with small non-cleaved-cell and large-cell lymphoma consecutively treated…
Comparison
Hematopoietic colony-stimulating factors in… vs No CSF
Design
Cohort
Authors
Loading...
CSF coadministration with vincristine was associated with severe neuropathy; hypothesis-generating in this small cohort and should not yet change practice.
Cohort (n=54)
Does the administration of hematopoietic colony-stimulating factors (CSFs) increase the risk of severe atypical neuropathy in lymphoma patients treated with vincristine?
Administration of hematopoietic colony-stimulating factors can precipitate severe atypical neuropathy when given in conjunction with vincristine in lymphoma patients.
Weintraub et al. (1996) conducted a cohort in Small non-cleaved-cell (SNCL) and large-cell lymphoma (LCL) (n=54). Hematopoietic colony-stimulating factors (CSFs) vs. No CSF was evaluated on Severe atypical neuropathy (SAN). Administration of hematopoietic colony-stimulating factors in conjunction with vincristine was significantly associated with the development of severe atypical neuropathy.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: